Drucker Wealth 3.0 LLC Has $2.38 Million Stake in Becton, Dickinson and Company $BDX

Drucker Wealth 3.0 LLC trimmed its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 14.4% during the second quarter, Holdings Channel.com reports. The firm owned 13,565 shares of the medical instruments supplier’s stock after selling 2,290 shares during the period. Drucker Wealth 3.0 LLC’s holdings in Becton, Dickinson and Company were worth $2,381,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of BDX. Brighton Jones LLC raised its position in shares of Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 877 shares during the period. Pallas Capital Advisors LLC raised its position in shares of Becton, Dickinson and Company by 23.8% during the first quarter. Pallas Capital Advisors LLC now owns 2,223 shares of the medical instruments supplier’s stock worth $509,000 after purchasing an additional 427 shares during the period. GAMMA Investing LLC raised its position in Becton, Dickinson and Company by 29.9% in the 1st quarter. GAMMA Investing LLC now owns 3,250 shares of the medical instruments supplier’s stock valued at $744,000 after buying an additional 748 shares during the last quarter. SG Americas Securities LLC raised its position in Becton, Dickinson and Company by 53.5% in the 1st quarter. SG Americas Securities LLC now owns 9,088 shares of the medical instruments supplier’s stock valued at $2,082,000 after buying an additional 3,168 shares during the last quarter. Finally, Integrated Advisors Network LLC raised its position in Becton, Dickinson and Company by 37.3% in the 1st quarter. Integrated Advisors Network LLC now owns 1,830 shares of the medical instruments supplier’s stock valued at $419,000 after buying an additional 497 shares during the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, Director Claire Fraser sold 917 shares of the firm’s stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the sale, the director directly owned 22,226 shares of the company’s stock, valued at $4,167,375. This trade represents a 3.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Michael David Garrison sold 1,185 shares of Becton, Dickinson and Company stock in a transaction dated Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the sale, the executive vice president directly owned 4,887 shares of the company’s stock, valued at approximately $881,077.23. This trade represents a 19.52% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 3,023 shares of company stock valued at $562,036. Insiders own 0.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on BDX. Argus increased their price target on Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Piper Sandler reissued a “neutral” rating and issued a $200.00 price target (up from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Weiss Ratings reissued a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Wednesday. Wells Fargo & Company increased their price target on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a research report on Friday, August 8th. Finally, Morgan Stanley increased their price target on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a research report on Monday, August 11th. Three analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, Becton, Dickinson and Company presently has a consensus rating of “Hold” and an average price target of $205.40.

Becton, Dickinson and Company Trading Down 1.4%

Shares of Becton, Dickinson and Company stock opened at $186.41 on Friday. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99. The firm has a market cap of $53.43 billion, a PE ratio of 33.53, a P/E/G ratio of 1.48 and a beta of 0.25. The stock has a fifty day moving average price of $190.07 and a 200-day moving average price of $186.32. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The firm had revenue of $5.32 billion during the quarter. Equities research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th were given a dividend of $1.04 per share. The ex-dividend date of this dividend was Monday, September 8th. This represents a $4.16 annualized dividend and a dividend yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 74.82%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.